KALV - カ―ビラン・セラピュ―ティクス （KalVista Pharmaceuticals Inc.） カ―ビラン・セラピュ―ティクスKALVのチャート
KALVの企業情報
| symbol | KALV |
|---|---|
| 会社名 | KalVista Pharmaceuticals Inc （カ―ビラン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 KalVista Pharmaceuticals Inc. formerly Carbylan Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery development and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate KVD818 is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001. カ―ビラン・セラピュ―ティクスは、米国のバイオ医薬品会社。満たされていない医療ニ―ズに対応する併用療法の開発と商業化に焦点を当て事業を展開する。変形性膝関節症に関連する痛みを治療するための医薬品として、関節内注射用製品候補であるハイドロス-TAを提供する。本社所在地はカリフォルニア州。 KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with a Phase 2 clinical trial expected to initiate in the second quarter of 2021. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial. |
| 本社所在地 | 55 Cambrigge Parkway Suite 901E Cambridge MA 02142 USA |
| 代表者氏名 | Richard Aldrich リチャード・アルドリッチ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 857-999-0075 |
| 設立年月日 | 38047 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 33人 |
| url | www.kalvista.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kalv |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -20.06300 |
| 終値（lastsale） | 17.465 |
| 時価総額（marketcap） | 300043233.455 |
| 時価総額 | 時価総額（百万ドル） 339.64240 |
| 売上高 | 売上高（百万ドル） 12.01600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 291.78640 |
| 当期純利益 | 当期純利益（百万ドル） -15.90700 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 31 July 2018 Kalvista Pharmaceuticals Inc revenues increased from $96K to $3.7M. Net loss increased 2% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.5M to $8.4M (expense) General and administrative increase of 14% to $2.4M (expense). |
KALVのテクニカル分析
KALVのニュース
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023/02/27 11:36:00 Finanz Nachrichten
Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU - Real-word evidence and patient survey data demo…
Investing in KalVista Pharmaceuticals Inc. (KALV) might be a great opportunity, but the stock is a bit undervalued 2023/02/16 14:40:00 US Post News
In Wednesday’s session, KalVista Pharmaceuticals Inc. (NASDAQ:KALV) marked $7.73 per share, down from $7.93 in the previous session. While KalVista Pharmaceuticals Inc. has underperformed by -2.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KALV fell by -50.39%, with highs and lows ranging from $17.34 to […]
Make a hit with This stocks: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV -2.52%), Otonomo Technologies Ltd. (NASDAQ:OTMO 5.91%), Tenaya Therapeutics, Inc. (NASDAQ:TNYA -6.42%) 2023/02/16 12:28:53 Stock Equity
Technical analysis of these three Hot stocks (KALV, OTMO, TNYA) KalVista Pharmaceuticals, Inc. a USA based Biotechnology Company, belongs to a Healthcare Sector. Otonomo Technologies Ltd. a Israel based Software … The post Make a hit with This stocks: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV -2.52%), Otonomo Technologies Ltd. (NASDAQ:OTMO 5.91%), Tenaya Therapeutics, Inc. (NASDAQ:TNYA -6.42%) appeared first on Stocks Equity .
KalVista stock rises on regulatory guidance for hereditary angioedema therapy 2023/02/14 12:06:34 Seeking Alpha
KalVista Pharmaceuticals (KALV) reported clinical trial and regulatory updates for its lead drug sebetralstat, a potential oral on-demand therapy for hereditary angioedema ((HAE)) attacks
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet 2023/02/10 11:36:00 Finanz Nachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors toda…
Investing in KalVista Pharmaceuticals Inc. (KALV) might be a great opportunity, but the stock is a bit undervalued 2022/11/01 14:08:00 US Post News
A share of KalVista Pharmaceuticals Inc. (NASDAQ:KALV) closed at $5.07 per share on Monday, down from $5.11 day before. While KalVista Pharmaceuticals Inc. has underperformed by -0.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KALV fell by -71.80%, with highs and lows ranging from $18.45 […]
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema 2022/10/31 10:46:00 Finanz Nachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, tod…
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema 2022/10/31 10:45:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat. Sebetralstat is currently being developed in the phase 3 KONFIDENT clinical trial as a potential on-demand treatment for h
Do investors need to be concerned about KalVista Pharmaceuticals Inc. (KALV)? 2022/10/28 13:08:00 US Post News
A share of KalVista Pharmaceuticals Inc. (NASDAQ:KALV) closed at $5.01 per share on Thursday, up from $4.70 day before. While KalVista Pharmaceuticals Inc. has overperformed by 6.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KALV fell by -69.53%, with highs and lows ranging from $18.45 […]
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat 2022/10/19 10:45:00 Wallstreet:Online
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica. The Journal of Medicinal Chemistry article focuses on the medicinal chemistry KalVista
Investing in KalVista Pharmaceuticals Inc. (KALV) might be a great opportunity, but the stock is a bit undervalued 2022/11/01 14:08:00 US Post News
A share of KalVista Pharmaceuticals Inc. (NASDAQ:KALV) closed at $5.07 per share on Monday, down from $5.11 day before. While KalVista Pharmaceuticals Inc. has underperformed by -0.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KALV fell by -71.80%, with highs and lows ranging from $18.45 […]
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema 2022/10/31 10:46:00 Finanz Nachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, tod…
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema 2022/10/31 10:45:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat. Sebetralstat is currently being developed in the phase 3 KONFIDENT clinical trial as a potential on-demand treatment for h
Do investors need to be concerned about KalVista Pharmaceuticals Inc. (KALV)? 2022/10/28 13:08:00 US Post News
A share of KalVista Pharmaceuticals Inc. (NASDAQ:KALV) closed at $5.01 per share on Thursday, up from $4.70 day before. While KalVista Pharmaceuticals Inc. has overperformed by 6.60%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KALV fell by -69.53%, with highs and lows ranging from $18.45 […]
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat 2022/10/19 10:45:00 Wallstreet:Online
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica. The Journal of Medicinal Chemistry article focuses on the medicinal chemistry KalVista